TY - JOUR
T1 - Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma
AU - Rajkumar, S. Vincent
AU - Fonseca, Rafael
AU - Dewald, Gordon W.
AU - Therneau, Terry M.
AU - Lacy, Martha Q.
AU - Kyle, Robert A.
AU - Greipp, Philip R.
AU - Gertz, Morie A.
N1 - Funding Information:
Supported in part by Program Project Grant CA 62242, National Cancer Institute, National Institutes of Health.
PY - 1999/8
Y1 - 1999/8
N2 - Chromosomal abnormalities have biologic and prognostic significance in multiple myeloma, especially among patients with relapsed disease. We report the relationship between chromosomal abnormalities and known prognostic factors such as plasma cell labeling index (PCLI) and bone marrow plasma cell involvement in 75 consecutive patients undergoing autologous stem cell transplantation for relapsed or refractory myeloma. Thirty of 70 patients (43%) had a chromosomally abnormal clone in their bone marrow, and in most cases the karyotype was complex (>3 abnormalities). Patients with an abnormal clone on cytogenetic analysis had a higher PCLI (median, 1.4) than patients with a normal karyotype (0.2) (P < 0.001). Bone marrow plasma cell percentage also differed: median 48% versus 20%, respectively (P < 0.001). The PCLI and bone marrow plasma cell percentage correlated positively with the percentage of abnormal metaphases on conventional cytogenetic analysis: rho 0.60 (P < 0.001) and 0.46 (P < 0.001), respectively. We categorized patients into those with 20% or more abnormal metaphases, less than 20% abnormal metaphases, and only normal metaphases. The median PCLI values were 3.3, 1.1, and 0.3, respectively (P < 0.001). The bone marrow plasma cell percentage median values were 62%, 40%, and 25%, respectively (P = 0.003). Chromosomal abnormalities may offer a proliferative advantage to the neoplastic plasma cell, thereby leading to an unfavorable outcome. Copyright (C) 1999 Elsevier Science Inc.
AB - Chromosomal abnormalities have biologic and prognostic significance in multiple myeloma, especially among patients with relapsed disease. We report the relationship between chromosomal abnormalities and known prognostic factors such as plasma cell labeling index (PCLI) and bone marrow plasma cell involvement in 75 consecutive patients undergoing autologous stem cell transplantation for relapsed or refractory myeloma. Thirty of 70 patients (43%) had a chromosomally abnormal clone in their bone marrow, and in most cases the karyotype was complex (>3 abnormalities). Patients with an abnormal clone on cytogenetic analysis had a higher PCLI (median, 1.4) than patients with a normal karyotype (0.2) (P < 0.001). Bone marrow plasma cell percentage also differed: median 48% versus 20%, respectively (P < 0.001). The PCLI and bone marrow plasma cell percentage correlated positively with the percentage of abnormal metaphases on conventional cytogenetic analysis: rho 0.60 (P < 0.001) and 0.46 (P < 0.001), respectively. We categorized patients into those with 20% or more abnormal metaphases, less than 20% abnormal metaphases, and only normal metaphases. The median PCLI values were 3.3, 1.1, and 0.3, respectively (P < 0.001). The bone marrow plasma cell percentage median values were 62%, 40%, and 25%, respectively (P = 0.003). Chromosomal abnormalities may offer a proliferative advantage to the neoplastic plasma cell, thereby leading to an unfavorable outcome. Copyright (C) 1999 Elsevier Science Inc.
UR - http://www.scopus.com/inward/record.url?scp=0032819014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032819014&partnerID=8YFLogxK
U2 - 10.1016/S0165-4608(99)00009-6
DO - 10.1016/S0165-4608(99)00009-6
M3 - Article
C2 - 10459351
AN - SCOPUS:0032819014
SN - 0165-4608
VL - 113
SP - 73
EP - 77
JO - Cancer Genetics and Cytogenetics
JF - Cancer Genetics and Cytogenetics
IS - 1
ER -